1.24
price up icon85.57%   0.5718
pre-market  Pre-market:  1.09   -0.15   -12.10%
loading
Kazia Therapeutics Limited Adr stock is currently priced at $1.24, with a 24-hour trading volume of 223.50M. It has seen a +85.57% increased in the last 24 hours and a +373.10% rose in the past month. The chart indicates a potential bullish trend, as the stock is above the $0.6727 pivot point. If it approaches the $1.48 resistance level, significant changes may occur.
Previous Close:
$0.6682
Open:
$1.035
24h Volume:
223.50M
Market Cap:
$36.94M
Revenue:
-
Net Income/Loss:
$-13.52M
P/E Ratio:
-1.6757
EPS:
-0.74
Net Cash Flow:
$-10.03M
1W Performance:
+489.63%
1M Performance:
+373.10%
6M Performance:
+254.29%
1Y Performance:
+24.00%
1D Range:
Value
$0.913
$1.58
52W Range:
Value
$0.1866
$1.58

Kazia Therapeutics Limited Adr Stock (KZIA) Company Profile

Name
Name
Kazia Therapeutics Limited Adr
Name
Phone
01161298780088
Name
Address
140 WICKS RD, NEW SOUTH WALES 2113, NSW
Name
Employee
9
Name
Twitter
@KaziaTx
Name
Next Earnings Date
2024-03-25
Name
Latest SEC Filings
Name
KZIA's Discussions on Twitter

Kazia Therapeutics Limited Adr Stock (KZIA) Upgrades & Downgrades

Date Action Analyst Rating Change
Oct-14-21 Initiated Maxim Group Buy
Jan-05-21 Initiated H.C. Wainwright Buy

Kazia Therapeutics Limited Adr Stock (KZIA) Financials Data

Kazia Therapeutics Limited Adr (KZIA) Net Income 2024

KZIA net income (TTM) was -$13.52 million for the quarter ending June 30, 2023.
loading

Kazia Therapeutics Limited Adr (KZIA) Cash Flow 2024

KZIA recorded a free cash flow (TTM) of -$10.03 million for the quarter ending June 30, 2023.
loading

Kazia Therapeutics Limited Adr (KZIA) Earnings per Share 2024

KZIA earnings per share (TTM) was -$0.74 for the quarter ending June 30, 2023.
loading
Kazia Therapeutics Ltd is an oncology-focused biotechnology company, developing innovative anti-cancer drugs. The group is developing paxalisib, a potential treatment for glioblastoma; Cantrixil, being developed for the treatment of ovarian cancer; and Others. The company is also developing EVT801 for the treatment of various tumors.
$150.50
price up icon 3.05%
$83.91
price up icon 1.97%
$26.24
price up icon 2.06%
$84.70
price up icon 4.18%
$461.72
price down icon 1.18%
$261.02
price up icon 1.26%
Cap:     |  Volume (24h):